Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1993-09-07
1995-09-26
Cintins, Marianne M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514399, 514401, 514471, A61K 3134, A61K 31415
Patent
active
054534283
ABSTRACT:
In accordance with the present invention, neuropsychiatric symptoms of apathy-amotivation syndrome and particularly those symptoms in: Alzheimer's disease, multiple sclerosis, Huntington's chorea, frontal lobe lesions, and AIDS dementia can be ameliorated by treating a patient with a histamine H.sub.2 -antagonist that passes the blood-brain barrier. Suitable H.sub.2 -antagonists include famotidine and ranitidine. The H.sub.2 -antagonists may be co-administered with other compounds which are known to be useful in the treatment of the above neuropsychiatric conditions, and in one aspect of the invention can be formulated with such other compounds into a therapeutic composition.
REFERENCES:
patent: 4757060 (1986-04-01), Lukacscko
patent: 4806548 (1989-02-01), Ivanova et al.
patent: 5070101 (1991-12-01), Kaminski
patent: 5177081 (1993-01-01), Kaminski
Chem. Abstract 103-52159 y (1985).
Chem. Abstract 110:107925 x (1989).
Chem. Abstract 104:28834 Q (1986).
Kaminski et al., Effect of famotidine on deficit symptoms of schizophrenia, The Lancet, (1990) vol. 335, pp. 1351-1352.
Pickar et al., Neurochemical and Neural Mechanisms . . . , Mod. Probl. Pharmacopsychiatry Basel, (1990) vol. 24 pp. 124-151.
Morrison et al., Positive and Negative Symptoms in Schizophrenia, The Journal of Nervous and Mental Disease, (1990) vol. 178, No. 6 pp. 377-384.
Carpenter et al., Deficit and Nondeficit Forms of Schizophrenia . . . , Am. J. Psychiatry, (1988) vol. 145, No. 5 pp. 578-583.
Wyatt et al., Schizophrenia, just the facts . . . , Schizophrenia Research, (1988) vol. 1 pp. 3-18.
Mesulam, Schizophrenia and Brain, The New England Journal of Medicine, (1990) vol. 322, No. 12 pp. 842-844.
Schwartz et al., Properties and Roles of the Three Subclasses of Histamine . . . , J. Exp. Biol., printed in Great Britain, (1986) vol. 124, pp. 203-224.
Itoh et al., Effects of Nociceptive Stimuli on Brain Histamine Dynamics, Japan, J. Pharmacol. (1989) vol. 49, pp. 449-454.
Gogas et al., Inhibition of Naloxone-Resistant Antinociception . . . , The Journal of Pharmacology and Experimental Therapeutics, (1989) vol. 248, No. 1.
Hough et al., A Role for Histamine and Histamine H.sub.2 -Receptors . . . , Life Sciences, (1985) vol. 36, pp. 859-866.
Prell, Ann. Rev. Neurosci (1986) vol. 9, pp. 209-254.
Life Sciences, (1985) vol. 36, pp. 859-866.
Heleniak et al., Histamine Methylation in Schizophrenia, Medical Hypotheses, (1989) vol. 30, pp. 167-174.
Heleniak et al., Histamine and Prostaglandins in Schizophrenia, Journal of Orthomolecular Psychiatry, vol. 14, No. 3, pp. 162-177, 1988.
Lucca et al., Biochemical Investigation of Histidinemia . . . Bil. Psychiatry, (1990) vol. 27, pp. 69-75.
Hough, Cellular Localization and Possible Functions for Brain Histamine . . . , Progress in Neurobiology, (1988) vol. 30, pp. 469-505.
White et al., Behavioural effects of histamine and its antagonists: a review . . . , Psychopharmacology, (1988) vol. 95, pp. 1-14.
Emsley et al., Water Excretion and Plasma Vasopressin in Psychotic Disorders, Am. J. Psychiatry (1989) vol. 146, No. 2, pp. 250-253.
Specht et al., Histamine-Elicited Drinking in Weanling and Adult Rate, Physiology & Behavior, (1989) vol. 45, pp. 63-70.
Koczapski et al., Individual Differences in Serum Sodium Level . . . , Am. J. Psychiatry, (1989) vol. 146, No. 12 pp. 1614-1615.
USP DI, (1990), "Histamine H.sub.2 -Receptor Antagonists (systemic)", pp. 1496-1505.
Gelenberg, "Famotidine for Schizophrenia? --Biological Therapies in Psychiatry" (Newsletter) (1990), vol. 13, No. 11 pp. 41 and 44.
Berkow et al., "The Merck Manual of Diagnosis and Therapy" 14th Edition, published by Merck, Sharp & Dohne Research Laboratorie, (1982), pp. 1359-1362 and 2336-2337.
Bianchine, "Drugs for Parkinson's Disease, Spasticity, and Acute Muscle Spasms", MacMillan Publishing Company, Goodman and Gilman's The Pharmacological Basis of Therapeutics, (1985), 7th Ed., Chap. 21, pp. 473-486.
Engelhardt et al., "Antiparkinsonism Drugs", Medicinal Chemistry, (1985) 3rd Ed. Part II, pp. 1538-1543.
Growden et al., "Distinctive Aspects of Cognitive Dysfunction in Parkinson's Disease", Advances in Neurology, (1990), vol. 53, pp. 3675-3737, Parkinson's Disease: Anatomy, Pathology, and Therapy.
Danilczyk et al., "Psychiatric Complications and Shift of Death Age in Parkinson's Disease", Advances in Neurology, (1990), vol. 53, pp. 405-410 Parkinson's Disease: Anatomy, Pathology and Therapy.
Calne et al., "Parkinson's Disease, Motoneuron Disease and Alzheimer's Disease: Origins and Interrelationship", Advances in Neurology, (1990), vol. 53:355-360.
Agid et al., "The Efficacy of Levodopa Treratment Declines in the Course of Parkinson's Disease: Do Nondopaminergic Lesions Play a Role?" Advances in Neurology, (1990), vol. 53, pp. 83-100 Parkinson's Disease: Anatomy, Pathology and Therapy.
Cummings, "Depression and Parkinson's Disease: A Review", Am J. Psychiatry, (1992), 149:4, pp. 443-454.
Garbarg et al., "Brain Histidine Decarboxylase Activity in Parkinson's Disease", The Lancet, (1983), pp. 74-75.
Coelho et al., "Decrease in Blood Histamine in Drug-Treated Parkinsonian Patients", Molecular and Chemical Neuropathology, (1991), vol. 14, pp. 77-85.
Poirier et al., "Debrisoquine Metabolism in Parkinsonian Patients Treated with Antihistamine Drugs", The Lancet, (1987), p. 386.
Nakamura et al., "Histochemistry of MPTP Oxidation in the Rat Brain: Sites of Synthesis of the Parkinsonism-Inducing Toxin MPP," Neuroscience Letters, (1986), vol. 65, pp. 321-325.
Cumming et al., "Cerebral Histamine Levels are Unaffected by MPTP Administration in the Mouse", European Journal of Pharmacology, (1989), vol. 166, pp. 299-301.
Knigge et al., "The Role of Histamine in the Neuroendocrine Regulation of Pituitary Hormone Secretion", Acta Endocrinologica (Copenh), (1991), vol. 124, pp. 609-619.
Cumming et al., "Cerebral Histamine Levels Are Unaffected By MPTP Administration in The Mouse", European Journal of Pharmacology, (1990), vol. 184, pp. 299-301.
Oish et al., "Is Monoamine Turnover in the Brain Regulated by Histamine H.sub.3 Receptors?", European Journal of Pharmacology, (1990), vol. 184, pp. 135-142.
Cumming et al., "High Affinity Histamine Binding Site Is the H.sub.3 Receptor: Characterization and Autoradiographic Localization in Rat Brain", Synapse 8, (1991), pp. 144-151.
Chiavegatto et al., "Effects of Prenatal Diphenydramine Exposure on Dopaminergic Function in Adult Rats", Pharmacology, Biochemistry & Behavior, (1991), vol. 140, pp. 191-193.
Matzen et al., "Brain Regulation of Renin Secretion Involves Central Histaminergic Neurons", Neuroendocrinology, (1990), vol. 52, pp. 175-180.
Sakai et al., "Effects of Thioperamide, A Histamine H.sub.3 Receptor Antagonist, on Locomotor Activity and Brain Histamine Content in Mast Cell-Deficient W/W Mice", Life Sciences, (1991), vol. 48, pp. 2397-2404.
Onodera et al., "Pharmacological Characteristics of Catalepsy Induced by Intracerebroventricular Administration of Histamine in Mice: The Importance of Muscarinic Step in Central Cholinergic Neurons", Birkhauser Verlag, Basel, Agents and Actions, (1991), vol. 33,pp. 143-146.
Knigge, "Histaminergic Regulation of Prolactin Secretion", (1990), vol. 37, No. 2, pp. 109-124.
Eisen et al., "Amyotrophic Lateral Sclerosis, Parkinson's Disease and Alzheimer's Disease: Phylogenetic Disorders of the Human Neocortex Sharing Many Characteristics", Can. J. Neurol. Sci., (1992), vol. 19, pp. 117-120.
Dooneief et al., "An Estimate of the Incidence of Depression in Idiopathic Parkinson's Disease", Arch Neurol, (1992), vol. 49.
Sharpe, "Auditory Attention in Early Parkinson's Disease: An Impairment in Focused Attention", Neuropsychologia, (1992), vol. 30, No. 1, pp. 101-106.
Marin, Am. J. Psychiatry 147:22-30 (1990).
Marin, J. Neuropsychiatry and Clinical Neurosci., 3:243-254 (1991).
Starkstein et al., J. Neuropsychiatry, 4:134-139 (1992).
Bozzola et al., Arch. Neurol., 49:297-300 (1992).
Burns et al., J. Nervous and Mental Dis., 178:20-26, (1990).
Mendez et al., Neurol., 39:349-354 (1989).
Robinson et al., Brain, 107:81-93 (1984).
House et al., Br. J. Psychiat
Cintins Marianne M.
MacMillan Keith
The Mount Sinai School of Medicine of the City of New York
LandOfFree
Method and composition for the treatment of apathy-amotivation s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and composition for the treatment of apathy-amotivation s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and composition for the treatment of apathy-amotivation s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1551984